Mapping an enzyme offers clues to treating rare genetic disease
Researchers at the Icahn School of Medicine at Mount Sinai have mapped an enzyme that could be targeted to develop new treatments for glutaric aciduria type 1 (GA1), a rare genetic disorder that can lead to brain damage, revealing new details about how the enzyme works and how its activity is controlled. The findings were published in Science Advances.
We haven't written up this one. Medical Xpress has the full story — the link below goes straight to it.
